Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05448807

Effectiveness of Phentolamine Mesylate as a Reversing Agent for Local Anesthesia in Children

Local anaesthesia is considered one of the most alarming and non-comfortable dental procedures for children. This goes back to the persisting effect of the local anaesthesia after finishing dental procedures. The effect of Local anaesthesia can last from 3 to 5 hours due to the presence of vasoconstrictor. The U.S Food and Drug Administration (FDA approved the use of phentolamine mesylate (Oraverse) in May 2008 to be used as a drug in reversing the numbing effect of Local anaesthesia by decreasing the time needed to restore the normal functions of the mouth

Recruiting

Interested in participating?

Request Info

Key information

Age range

5 year–7 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Cairo University

Cairo, El Manial, 11562, Egypt

Location status: Recruiting

Location contact

Alaa Saad, Bachelor degree of science

PRINCIPAL_INVESTIGATOR

Alaa Saad, bachelor degree of science

CONTACT

[email protected]

00201144942076

Passant Nagi

CONTACT

[email protected]

00201280557107

Passant Nagi

SUB_INVESTIGATOR

About this study

Local anesthesia is the most common method for pain control during any dental procedures, but it is also one of the factors that can trigger discomfort and anxiety in children. Local anesthetics are primarily used to reversibly block action potentials that create impulse conduction along neural axons carrying sensory or motor signals. This occurs by blocking voltage-gated sodium channels. A prospective study of 320 children by College et al., (2000), reported soft tissue trauma frequency as 18%, 16%, 13% and 7% in children who are; less than 4, 4-7, 8-11 and more than 12 years old, respectively following inferior alveolar nerve block anesthesia and its numbing effect.

The search for a pharmacologic means of minimizing postoperative soft tissue anesthesia has focused on phentolamine mesylate (PM), where an injectable form has been developed. Following the administration of local anesthetic with vasoconstrictor, a subsequent phentolamine injection into the same location enhances the redistribution of the local anesthetic away from the injection site as it is an alpha-adrenergic blocking agent, explaining the more rapid return of normal intraoral and perioral sensation.

An intra-oral preparation of PM for the reversal of soft tissue anesthesia was approved by the FDA in May 2008, to be used for patients > 6 years of age and weighing > 15 kg. Later, in March 2016, the FDA approved its use in pediatric patients 3 years and older. Dosage form of OraVerse (phentolamine mesylate) is 0.4 mg/1.7 ml solution per cartridge. Its maximum dose is 2 cartridges in adults. The first published placebo-controlled phase two study reported that, in 10- to 58-year-old dental patients, an injection of phentolamine, at a one-to-one ratio at the site of the previous injection of local anesthesia, accelerated median recovery time to normal sensation of the upper and lower lips by 85 minutes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children aged 5-7 years.

  • Patients in need of dental procedures requiring local anaesthesia.
  • Healthy Children without any systemic or mental disorders.
  • Normal lip sensation before administration of LA.
  • Normal paediatric functional assessment battery (pFAB) for smiling, speaking and drinking and absence of drooling.

Exclusion criteria

  • Children seeking dental treatment that does not necessitate local anaesthesia.
  • Children who didn't achieve profound numbness requiring additional anaesthesia.
  • Children who lack the ability to distinct the anaesthetised numb side from the non-anaesthetised one.
  • Children who are not willing to participate in the study.

Treatment and study plan

OraVerse

Drug

Phentolamine mesylate is a vaso-dilator that was used for treating dermal necrosis and severe hypertension cases since 1952. It is alpha-adrenergic antagonist. Oraverse is supplied in a dose equal to the amount of LA taken in adults and children with weights more than 30 kg. While in children less than 30 kg, it is advised to use only half carpule according the manufacturer's instructions.

Other names: phentolamine mesylate

Primary outcomes

  1. Time to return to normal function

    Time frame: 2 hours

    it is the time needed for the soft intraoral tisues e.g lips, tongue to return to their normal functions after local anaesthesia

Secondary outcomes

  1. Incidence of self-inflicted soft tissue trauma

    Time frame: 2 hours

    we observe clinical signs of redness, swelling, hematoma or ulcers due to lip biting at dismal of each participant

  2. Cost effectiveness of oraverse

    Time frame: Through the completion of the study, with average 1 year

    we measure the cost effectiveness of the intervention drug through Incremental cost-effectiveness ratio (ICER) ICER=(C1-C0)/ (E1-E0) C1= cost of intervention drug C0= cost of control E1= effect of intervention drug E0= effect of control

  3. post-operative pain by 170 mm Heft-parker visual analogue scale (VAS)

    Time frame: the following 24 hours

    it is 170mm scale from 0 to 170 mm and it represents

    • no pain: corresponds to 0 mm.
    • mild pain: greater than 0 mm and less than or equal to 54 mm and included the description of faint and weak pain.
    • moderate pain: greater than 54 mm and less than 114 mm.
    • severe pain: equal to or greater than 114 mm to 170 mm and includes the description of strong and intense pain

Study contacts

Contact information is provided by the study sponsor or research team.

alaa saad abourawash

CONTACT

[email protected]

01144942076

passant nagy

CONTACT

[email protected]

01280557107

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

A Randomized Effectiveness of Phentolamine Mesylate as a Reversing Agent for Local Anesthesia in Decreasing Self- Inflicted Soft Tissue Trauma Following Local Anaesthesia Injection for Dental Procedure in Children: Randomized Clinical Trial

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 7, 2022
Registry last updated
Jul 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.